341 related articles for article (PubMed ID: 28883264)
21. Treatment of Relapsed/Refractory Multiple Myeloma.
Neri P; Bahlis NJ; Paba-Prada C; Richardson P
Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263
[TBL] [Abstract][Full Text] [Related]
22. Current therapeutic strategies for multiple myeloma.
Torimoto Y; Shindo M; Ikuta K; Kohgo Y
Int J Clin Oncol; 2015 Jun; 20(3):423-30. PubMed ID: 25855312
[TBL] [Abstract][Full Text] [Related]
23. How is patient care for multiple myeloma advancing?
Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
[TBL] [Abstract][Full Text] [Related]
24. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Dimopoulos MA; Richardson P; Lonial S
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):460-473. PubMed ID: 35148975
[TBL] [Abstract][Full Text] [Related]
25. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Afifi S; Michael A; Azimi M; Rodriguez M; Lendvai N; Landgren O
Pharmacotherapy; 2015 Dec; 35(12):1173-88. PubMed ID: 26684557
[TBL] [Abstract][Full Text] [Related]
26. Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting.
Garderet L; Cook G; Auner HW; Bruno B; Lokhorst H; Perez-Simon JA; Sahebi F; Scheid C; Morris C; van Biezen A; Sobh M; Michallet M; Gahrton G; Schönland S; Kröger N
Leuk Lymphoma; 2017 Apr; 58(4):797-808. PubMed ID: 27650125
[TBL] [Abstract][Full Text] [Related]
27. [Novel agents in multiple myeloma treatment].
Ito S
Rinsho Ketsueki; 2015 Oct; 56(10):2066-73. PubMed ID: 26458446
[TBL] [Abstract][Full Text] [Related]
28. Practical Approaches to the Management of Dual Refractory Multiple Myeloma.
Lee HC; Mark TM; Shah JJ
Curr Hematol Malig Rep; 2016 Apr; 11(2):148-55. PubMed ID: 26898556
[TBL] [Abstract][Full Text] [Related]
29. [Pomalidomide for multiple myeloma].
Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
[TBL] [Abstract][Full Text] [Related]
30. Management of relapsed multiple myeloma after autologous stem cell transplant.
Holstein SA; Richardson PG; Laubach JP; McCarthy PL
Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic approach for relapsed/refractory multiple myeloma: the logic and practice].
Kuroda J
Rinsho Ketsueki; 2017; 58(10):2058-2066. PubMed ID: 28978849
[TBL] [Abstract][Full Text] [Related]
32. Multiple Myeloma in the Time of COVID-19.
Al Saleh AS; Sher T; Gertz MA
Acta Haematol; 2020; 143(5):410-416. PubMed ID: 32305989
[TBL] [Abstract][Full Text] [Related]
33. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
34. [Multiple myeloma : What has been confirmed in therapy?].
Baertsch MA; Goldschmidt H
Internist (Berl); 2017 Dec; 58(12):1250-1257. PubMed ID: 29098319
[TBL] [Abstract][Full Text] [Related]
35. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Boudreault JS; Touzeau C; Moreau P
Expert Rev Hematol; 2017 Mar; 10(3):207-215. PubMed ID: 28110581
[TBL] [Abstract][Full Text] [Related]
36. All transplantation-eligible patients with myeloma should receive ASCT in first response.
Moreau P; Attal M
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):250-4. PubMed ID: 25696863
[TBL] [Abstract][Full Text] [Related]
37. Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity.
Cornell RF; Kassim AA
Bone Marrow Transplant; 2016 Apr; 51(4):479-91. PubMed ID: 26726946
[TBL] [Abstract][Full Text] [Related]
38. Current treatments for renal failure due to multiple myeloma.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Pharmacother; 2016 Nov; 17(16):2165-2177. PubMed ID: 27646819
[TBL] [Abstract][Full Text] [Related]
39. Progress and Paradigms in Multiple Myeloma.
Anderson KC
Clin Cancer Res; 2016 Nov; 22(22):5419-5427. PubMed ID: 28151709
[TBL] [Abstract][Full Text] [Related]
40. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
